Suven Life Sciences has received a product patent from Japan corresponding to new chemical entities used in the treatment of disorders associated with neurodegenerative diseases.
The patent is valid through 2034. The granted claims include the class of selective 5-HT4 compounds being developed as therapeutic agents and useful in treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson and schizophrenia.
Suven has a pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need. There is a huge market potential globally for such products, Chief Executive Officer Venkat Jasti said in a release on Monday.